This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Lung Cancer - Other

February 8, 2020
The newest version of the ASCO guidelines for lung cancer surveillance after curative lung cancer therapy is presented. The overall quality of supportive evidence is low, and the strength of recommendations is moderate. CT is recommended as the optimal imaging modality.
February 1, 2020
Individuals at high risk for lung cancer were randomized to low dose CT screening (years 0, 1, 3, and 5.5) or observation.  At 10 years the cumulative rate ratio for lung cancer death was 0.76 in the screened population of men (p=0.01) and 0.67 in the screened population of women, demonstrating a strong benefit for screening.  
January 10, 2020
Declines in US annual lung cancer mortality rates of 5% for men and 4% for women led improvements in overall cancer mortality rates in the latest update from the American Cancer Society. This is likely linked to efforts at decreasing tobacco use, improved screening, and newer systemic therapies.
January 10, 2020
Benign-appearing lung nodules identified on screening CTs are associated with an increased risk of lung cancer diagnosis 4 to 8 and 8 to 11 years after the scan (RRs 1.9 and 1.6, respectively).
October 21, 2019
Better cardiorespiratory fitness as quantified by treadmill exercise testing was associated with a substantially decreased likelihood of lung cancer in former smokers (77% reduction in very fit) and reduced mortality in smokers who subsequently developed lung cancer (85% reduction in very fit).
September 20, 2019
Immune checkpoint inhibitors have revolutionized treatment of non-small cell lung cancer. In this study, breath prophiles were collected from 143 patients and a single biomarker profile was created that detected responses to anti-PD-1 treatment with 89% accuracy.
August 22, 2019
This study of over 25,000 pts from the International Lung Cancer Consortium identified underweight and severly obese patients as having poorer survival than others, whereas a survival advantage was evident among patients who were overweight or mildly obese.  Decreased BMI (wt loss) was associated with poorer outcomes across all BMI categories.
August 21, 2019
An interesting discussion in this manuscript of a case-control study of 666 subjects.
August 20, 2019
Interesting follow-up study of 208 pulmonary ground -glass opacities in 160 subjects, with a yield of three adenocardinomas.
March 15, 2019
Drugs and Devices The US Food and Drug Administration (FDA) announced that the indications for the MitraClip™, made by Abbott, have been expanded to include secondary mitral regurgitation.